A study in the American Journal of Human Genetics suggests healthy individuals may pass on somatic mutations present in a small subset of their cells, playing a previously under-appreciated role in the risk of certain genetic conditions. Along with the new biological insights it provides, the work may eventually have clinical applications, the researchers noted, particularly for understanding how likely it is that a family that has one child with a rare genomic disorder will go on to have another.
PathoGenetix has filed for Chapter 7 bankruptcy in US Bankruptcy Court District of Massachusetts. The firm, formerly called US Genomics, had developed a genotyping technology called Genome Sequencing Scanning for detecting pathogens in environmental samples. Last year the company raised $10 million in a Series C financing round, and it was planning to launch its Resolution Microbial Genotyping System in the third quarter of this year with assays to identify and serotype Salmonella and pathogenic E. coli strains.
UK Prime Minster David Cameron has unveiled a £311 million ($523 million) investment package that includes a partnership between Genomics England and Illumina and will fund its national genome sequencing initiative, the 100,000 Genomes Project. As part of the plan Illumina will receive £78 million to support Genomics England with whole genome sequencing services, infrastructure, and expertise. In turn, Illumina has pledged to invest £162 million into the work in England over a four-year period.
This online seminar will discuss the discovery and evaluation of gene expression signatures associated with cancer treatment outcomes. These presentations will provide an overview of the promise of tumor microenvironment profiling in the radiation oncology setting, as well as the challenges in applying genomic methods to biomarker discovery.